60-Year-Old Drug May Hold Clues To Stopping Spread Of Breast Cancer
One of the oldest chemotherapy drugs in the world may be able to stop breast cancer spreading, according to a new study.
(Johns Hopkins Medicine) In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Sacituzumab, is an antibody that zeroes in on cancer cells. Like a homing missile, it delivers a 'warhead' in the form of a potent chemotherapy drug.
ConclusionsWe found no consistent association between pre-chemotherapy PIM defined by STOPP and outcomes.
Condition: HER2-positive Breast Cancer Intervention: Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor: Shandong University Not yet recruiting
Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR,...
In this study, to achieve the combined photothermal-chemotherapy of breast cancer, a pH-sensitive oxidized hyaluronic acid-decorated dihydroxyphenyl/hydrazide bifunctionalized hydroxyethyl chitosan (DHHC)-gold nanorod (GNR) conjugate was developed. DHHC was synthesized by successive dihydroxyphenylation and hydrazidation of hydroxyethyl chitosan through carbodiimide reaction and click chemistry, respectively. The conjugate was obtained by chemically bonding DHHC onto GNR via Au-catechol bonds. Doxorubicin (DOX) was loaded onto the conjugate via an acid-labile hydrazone linkage with a drug loading content of 5.1%. DOX-loade...
Introduction: Breast cancer (BC) “is the most frequent cancer in women worldwide, Forming 23% of all cancer cases in women. Now it's become the most common cancer both in developed and developing countries.
ConclusionIt seems that inexperienced physicians may profit from the use of EndoPredict® to avoid an overtreatment. In nodal negative patients and patients with a low Ki67 index, undertreatment can be avoided with the use of EndoPredict® (borderline significance). Further prospective studies with larger study cohorts are needed to further validate this tool.
Condition: Breast Cancer Intervention: Sponsor: Cancer Trials Ireland Recruiting
CONCLUSIONS: In the neoadjuvant setting, there is high- to low-certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full-text publication of a relevant neoadjuvant study for women with HER2-negative breast cancer for inclusion in an update of this review. PMID: 30776132 [PubMed - as supplied by publisher]